Drugs / Metformin immediate release (IR)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01525225 | Sep 2012 → Jun 2013 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-06-06 | AstraZeneca | Results AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin, saxagliptin and metformin for the treatment of type 2 diabetes astrazeneca.com ↗
Data in oral presentation demonstrate that the investigational combination of dapagliflozin, saxagliptin and metformin resulted in statistically significant reductions in HbA1c in patients uncontrolled on saxagliptin and metformin |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metformin immediate release (IR) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01525225 ↗ |
| Route | Oral | “Tablet, Oral” NCT01525225 ↗ |